198 related articles for article (PubMed ID: 33882406)
21. Serum untargeted metabolomics reveal metabolic alteration of non-small cell lung cancer and refine disease detection.
Li J; Liu K; Ji Z; Wang Y; Yin T; Long T; Shen Y; Cheng L
Cancer Sci; 2023 Feb; 114(2):680-689. PubMed ID: 36310111
[TBL] [Abstract][Full Text] [Related]
22. Does early PET/CT assesment of response to chemotherapy predicts survival in patients with advanced stage non-small-cell lung cancer?
Ordu C; Selcuk NA; Erdogan E; Angin G; Gural Z; Memis H; Yencilek E; Dalsuna S; Pilanci K
Medicine (Baltimore); 2014 Dec; 93(28):e299. PubMed ID: 25526475
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of Classifier Performance for Multiclass Phenotype Discrimination in Untargeted Metabolomics.
Trainor PJ; DeFilippis AP; Rai SN
Metabolites; 2017 Jun; 7(2):. PubMed ID: 28635678
[TBL] [Abstract][Full Text] [Related]
24. Support vector machine-based prediction of local tumor control after stereotactic body radiation therapy for early-stage non-small cell lung cancer.
Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Guckenberger M
Int J Radiat Oncol Biol Phys; 2014 Mar; 88(3):732-8. PubMed ID: 24411630
[TBL] [Abstract][Full Text] [Related]
25. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
Xu TP; Shen H; Liu LX; Shu YQ
Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
[TBL] [Abstract][Full Text] [Related]
26. Applicability of a prognostic CT-based radiomic signature model trained on stage I-III non-small cell lung cancer in stage IV non-small cell lung cancer.
de Jong EEC; van Elmpt W; Rizzo S; Colarieti A; Spitaleri G; Leijenaar RTH; Jochems A; Hendriks LEL; Troost EGC; Reymen B; Dingemans AC; Lambin P
Lung Cancer; 2018 Oct; 124():6-11. PubMed ID: 30268481
[TBL] [Abstract][Full Text] [Related]
27. A tutorial review: Metabolomics and partial least squares-discriminant analysis--a marriage of convenience or a shotgun wedding.
Gromski PS; Muhamadali H; Ellis DI; Xu Y; Correa E; Turner ML; Goodacre R
Anal Chim Acta; 2015 Jun; 879():10-23. PubMed ID: 26002472
[TBL] [Abstract][Full Text] [Related]
28. Reduction of Serum Cytokeratin-3A9 is Associated with Chemotherapeutic Response in Patients with Non-Small Cell Lung Cancer.
Shi GL; Wu ED; Sun Y; Yin YJ; Song CX
Clin Lab; 2015; 61(5-6):497-504. PubMed ID: 26118182
[TBL] [Abstract][Full Text] [Related]
29. Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.
Lee HY; Lee KS; Hwang HS; Lee JW; Ahn MJ; Park K; Kim TS; Yi CA; Chung MJ
Korean J Radiol; 2010; 11(6):618-26. PubMed ID: 21076587
[TBL] [Abstract][Full Text] [Related]
30. Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma.
Chen Z; Gao Y; Huang X; Yao Y; Chen K; Zeng S; Mao W
J Pharm Biomed Anal; 2021 Apr; 197():113937. PubMed ID: 33609949
[TBL] [Abstract][Full Text] [Related]
31. Clinical investigation of efficacy of albumin bound paclitaxel plus platinum compounds as first-line chemotherapy for stage III/IV squamous non-small cell lung cancer.
Fang Y; Wang L; Xia GH; Shi MQ
Asian Pac J Cancer Prev; 2014; 15(17):7453-7. PubMed ID: 25227858
[TBL] [Abstract][Full Text] [Related]
32. Do the time to chemotherapy response and the dose intensity have an impact on patient outcome in advanced non-small cell lung cancer?
Radosavljevic D; Golubicic I; Gavrilovic D; Kezic I; Jelic S
J BUON; 2009; 14(2):203-9. PubMed ID: 19650167
[TBL] [Abstract][Full Text] [Related]
33. A metabolomic approach to lung cancer.
Hori S; Nishiumi S; Kobayashi K; Shinohara M; Hatakeyama Y; Kotani Y; Hatano N; Maniwa Y; Nishio W; Bamba T; Fukusaki E; Azuma T; Takenawa T; Nishimura Y; Yoshida M
Lung Cancer; 2011 Nov; 74(2):284-92. PubMed ID: 21411176
[TBL] [Abstract][Full Text] [Related]
34. Relationship between circulating tumor-associated autoantibodies and clinical outcomes in advanced-stage NSCLC patients receiving PD-1/-L1 directed immune checkpoint inhibition.
Tarhoni I; Wakefield CJ; Kollipara R; Fidler MJ; Batus M; Bonomi P; Borgia JA
J Immunol Methods; 2021 Mar; 490():112956. PubMed ID: 33434603
[TBL] [Abstract][Full Text] [Related]
35. Machine Learning-Assisted Recurrence Prediction for Patients With Early-Stage Non-Small-Cell Lung Cancer.
Janik A; Torrente M; Costabello L; Calvo V; Walsh B; Camps C; Mohamed SK; Ortega AL; Nováček V; Massutí B; Minervini P; Campelo MRG; Del Barco E; Bosch-Barrera J; Menasalvas E; Timilsina M; Provencio M
JCO Clin Cancer Inform; 2023 Jul; 7():e2200062. PubMed ID: 37428988
[TBL] [Abstract][Full Text] [Related]
36. Platinum-based chemotherapy in combination with PD-1/PD-L1 inhibitors: preclinical and clinical studies and mechanism of action.
Xue Y; Gao S; Gou J; Yin T; He H; Wang Y; Zhang Y; Tang X; Wu R
Expert Opin Drug Deliv; 2021 Feb; 18(2):187-203. PubMed ID: 32954856
[TBL] [Abstract][Full Text] [Related]
37. Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer.
Ahn BC; So JW; Synn CB; Kim TH; Kim JH; Byeon Y; Kim YS; Heo SG; Yang SD; Yun MR; Lim S; Choi SJ; Lee W; Kim DK; Lee EJ; Lee S; Lee DJ; Kim CG; Lim SM; Hong MH; Cho BC; Pyo KH; Kim HR
Eur J Cancer; 2021 Aug; 153():179-189. PubMed ID: 34182269
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B; Garrido P; Cortot AB; Johnson M; Murakami H; Gazzah A; Gil M; Bennouna J
Lung Cancer; 2020 Apr; 142():63-69. PubMed ID: 32114283
[TBL] [Abstract][Full Text] [Related]
39. [Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Xu CA; Su H; Liu JL; Li L; Zou HW
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):436-41. PubMed ID: 21875484
[TBL] [Abstract][Full Text] [Related]
40. Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential Treatment.
Maquilan G; Grover S; Xanthopoulos E; Evans TL; Aggarwal C; Langer CJ; Cohen RB; Stevenson JP; Simone CB; Rengan R
Am J Clin Oncol; 2018 Apr; 41(4):391-395. PubMed ID: 27100960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
